Method for constructing rotigotine transdermal patch IVIVC from in-vitro mouse skin
By using murine skin in vitro to perform penetration test and fitting of rotigotine transdermal patches, the problem of insufficient research on transdermal patches in the prior art was solved, and low-cost IVIVC fit was achieved to predict human body PK data provide strong guidance for subsequent experiments.
Patent Information
- Application Number
- CN202411307426.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, there are few studies on IVIVC for transdermal patches, and in vitro penetration tests mostly use human skin during the construction process. However, human skin is difficult to obtain and the quantity is limited, making it difficult to establish effective transdermal compound screening and evaluation methods.
In vitro penetration test was performed using murine skin and IVIVC fitting with human PK data. In vitro penetration experiment was performed by ex vivo animal skin retaining subcutaneous fascia, and the transdermal patch was calculated using Franz vertical diffusion cell and HPLC detection. Drug absorption fraction and permeability were linear regression fit.
Established an IVIVC relationship suitable for skin of different species, with low cost, good fitting of IVIVC, and the fitting curve correlation coefficient R2 of rats reached 0.9290. It can predict human PK data based on IVPT data of ex vivo rat skin, which is a subsequent Experimental guidance is provided.
Smart Images

Figure CN119000442A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for constructing an IVIVC of a rotigotine transdermal patch from isolated mouse skin, and in particular to an IVIVC construction method, which belongs to the technical field of in vivo and in vitro correlation research of transdermal patches. Background Art
[0002] Rotigotine, whose chemical name is (S)-2-(N-propyl-N-(2-(2-thiophene)ethyl)amino)-5-hydroxy-1,2,3,4-tetrahydronaphthalene, also known as rotigotine, is a dopamine receptor agonist commonly used to treat Parkinson's disease and restless legs syndrome.
[0003] IVIVC (InVivo-InVitroCorrelation): used to describe the relationship between the in vitro characteristics of a formulation (such as the in vitro flux of a drug) and the in vivo absorption behavior (such as in vivo plasma drug concentration). IVIVC means that in vitro drug behavior can be used to predict in vivo behavior. In vitro studies can also be better controlled, providing a more convenient and effective method for screening transdermal compounds or evaluating the performance of transdermal formulations. However, there are currently few IVIVC studies on transdermal patches, and in vitro permeation tests mostly use human skin during the construction process. However, in actual use, human skin is difficult to obtain and the quantity is very small. Summary of the invention
[0004] In order to solve the problems existing in the prior art, the present invention provides a method for constructing an IVIVC of a rotigotine transdermal patch using isolated mouse skin. The method uses mouse skin to conduct an in vitro permeation test and performs IVIVC fitting with human PK data.
[0005] The technical solution of the present invention is: taking ex vivo animal skin with subcutaneous fascia retained, and conducting an in vitro permeation experiment, and performing IVIVC fitting on the obtained IVPT data and human PK data.
[0006] The method for obtaining ex vivo animal skin is as follows: after killing the animal (rats, mice, nude mice), cut the skin, gently wipe the subcutaneous fat tissue with cotton wool, and pay attention to retaining the subcutaneous fascia tissue. For rat and mouse skin, anesthetize the rat or mouse by ether inhalation, carefully remove its abdominal hair, and ensure that there are no obvious scars on the skin surface. Then, kill the rat or mouse by ether inhalation, cut its abdominal skin, and gently wipe the subcutaneous fat tissue with cotton wool, but retain the subcutaneous fascia tissue. For nude mouse skin, after killing the nude mouse by cervical dislocation, cut its back skin, gently wipe the subcutaneous fat tissue with cotton wool, but retain the subcutaneous fascia tissue.
[0007] First, process the rotigotine transdermal patch, cut it into a circle of appropriate area, remove the release film on the surface, stick the patch on the skin to be tested, press gently to ensure a firm adhesion, fix the skin with a fixing clip and add the pre-configured receiving medium (PBS buffer solution with pH=6.5).
[0008] The device temperature was set to 32±0.5℃, the speed was set to 600rpm, and the receiving solution was PBS buffer solution with pH=6.5. 200uL of samples were taken at 1, 2, 3, 4, 6, 8, 10, 12 and 24h, and an equal amount of isothermal blank receiving solution was added. The samples were centrifuged at high speed and the supernatant was taken, and the samples were tested using HPLC.
[0009] The Wagner-Nelson equation was used to calculate the drug absorption fraction Fa of rotigotine transdermal patch in human body, and a linear regression fit was performed with the permeability Ft in isolated mouse skin.
[0010] The beneficial effects of the present invention are as follows: the method uses ex vivo mouse skin with subcutaneous fascia retained, and conducts an in vitro permeation experiment, after which the obtained IVPT data is fitted with human PK data. The present invention uses easy-to-obtain IVPT data of mouse skin to establish an IVIVC relationship with human PK data, so as to establish a method suitable for constructing IVIVC between skins of different species. The present invention can be used to predict human PK data based on IVPT data of ex vivo mouse skin, providing guidance and assistance for subsequent experiments. The method is low-cost and has good IVIVC fitting when conducting in vitro permeation tests, and the correlation coefficient R of the fitting curve of rats is 2 Reached 0.9290. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 The results of rotigotine transdermal patch permeation in different mouse skins for 24 hours in vitro. A is the cumulative permeation of rotigotine in 24 hours; B is the cumulative permeation curve (32±0.5℃, mean±SD, n=3).
[0012] Figure 2 is the regression curve equation of rotigotine in different skin types.
[0013] Figure 3 It is a schematic diagram of the structure of the Franz vertical diffusion cell. DETAILED DESCRIPTION
[0014] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments can be combined with each other. The present invention will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.
[0015] The method for constructing a rotigotine transdermal patch IVIVC from isolated rat skin comprises the following steps: 1. Acquisition of fresh skin samples: KM mice, SD rats and BALB / c nude mice commonly used in in vitro permeation tests were selected as skin models. Mice were killed by cervical dislocation, and the hair on their backs was carefully removed to ensure that there were no obvious scars on the skin surface. Rats were anesthetized by ether inhalation, and the hair on their backs was carefully removed to ensure that there were no obvious scars on the skin surface. Rats were then killed by ether inhalation and nude mice were killed by cervical dislocation. The back skin was cut and the subcutaneous fat tissue was gently wiped with absorbent cotton, but the subcutaneous fascia tissue was retained.
[0016] 2. In vitro permeation test The Franz vertical diffusion cell of Dalian Kexiang Company was used for the study. Its structure is as follows: Figure 3 The device temperature was set to 32±0.5℃, the rotation speed was set to 600rpm, and the receiving liquid was a PBS buffer solution with a pH of 6.5. The rotigotine transdermal patch was first processed and cut into pieces with an area of about 1.767cm 2 The patch is circular, the release film on the surface is removed, and the patch is attached to the skin to be tested. Press gently to ensure that the patch is firmly attached. After fixing the skin with a fixing clip, add the pre-configured receiving medium, and sample 200uL at 1, 2, 3, 4, 6, 8, 10, 12 and 24h respectively and add an equal amount of isothermal blank receiving solution. After the sample is centrifuged at high speed (10000rpm, 5min), the supernatant is taken and the sample is tested using HPLC. The cumulative release amount and cumulative release rate are calculated according to the following formula.
[0017]
[0018]
[0019] In the formula, Q t is the cumulative release per unit area (μg / cm 2 );C n is the RVS concentration of the nth sampling point (μg / mL); V is the volume of the diffusion cell (mL); V n is the sampling volume (mL); A is the effective diffusion area of the drug (cm 2 );R t is the cumulative release rate per unit area (%); M0 is the drug content per unit area of the patch.
[0020] The results of in vitro permeation of rotigotine transdermal patch (2.5 mg / 24 h) in three types of rat skin for 24 h are as follows Figure 1 shown. Figure 1Figure A shows the cumulative permeation of rotigotine in three types of mouse skin after 24 hours of in vitro permeation. The results show that the permeation of rotigotine in mouse, rat and nude mouse skin is 373.67±40.48μg / cm 2 , 137.69±20.77μg / cm 2 and 183.32±20.20μg / cm 2 . The cumulative permeation amount in mouse skin was the highest, and there was a significant difference compared with rats and nude mice (p < 0.001). The cumulative permeation amount was about 2 times that of nude mice and 2.7 times that of rats. That is, after 24 hours of penetration, the permeation amount of rotigotine transdermal patch in mouse skin was the highest, and there was a significant difference between the permeation amount of mouse skin and rats and nude mice. However, there was no significant difference in the cumulative permeation amount between rats and nude mice. Figure 1 Figure B shows the permeation curve of rotigotine transdermal patch in three types of mouse skin. It can be seen that the drug permeates into mouse skin within 1 hour, while it takes 4 hours for rats and nude mice to permeate. The analysis shows that the skin of mice is thinner and has abundant hair follicles, so the steady-state permeation rate of mice is significantly higher than that of rats and nude mice; the skin of nude mice is thin but has few hair follicles, while the skin of rats has many hair follicles but is thicker, so although the cumulative permeation of nude mice is slightly higher than that of rats, there is no significant difference.
[0021] 3. Calculation of in vivo absorption percentage According to the PK data of rotigotine transdermal patch in humans reported in the literature, Fa was calculated using the following formula: (Wagner-Nelson equation)
[0022] Where Fa is the absorbed fraction of the drug, C t is the blood drug concentration at time t; k el is the elimination rate constant, AUC 0→t AUC is the area under the plasma concentration-time curve from time 0 to time t. 0→∞ is the area of the plasma concentration-time curve from 0 to ∞.
[0023] 4. IVIVC fitting The IVPT data of rotigotine transdermal patch in three types of mouse skin were processed, and the permeability Ft of rotigotine transdermal patch in three types of mouse skin was obtained, and the Fa obtained from the human PK data processed by Wagner-Nelson equation was fitted with a linear regression equation.
[0024] Table 1 The absorption fraction Fa of rotigotine transdermal patch in human body and the in vitro permeability Ft in mouse, rat and nude mouse skin at the corresponding time
[0025] The results showed that Table 1 shows the absorption fraction of rotigotine transdermal patch in human body and the in vitro permeability in mouse, rat and nude mouse skin at the corresponding time. Table 2 shows the IVIVC equation and R of rotigotine transdermal patch in mouse skin. 2 , Figure 2 The following is the regression curve equation of rotigotine in different skins. It can be seen that the IVIVC fits well in the three types of mouse skin, and the best fit is in rats. The rat skin fits the human in vivo data more closely. Because rats are closer to human skin in terms of skin thickness and lipid content, the in vitro permeation results of rat skin fit the human in vivo absorption better than those of mice and nude mice.
[0026] Table 2 IVIVC equation of rotigotine transdermal patch in rat skin
[0027] The present invention constructs three types of ex vivo mouse (mouse, rat and nude mouse) skin to construct IVIVC of rotigotine transdermal patch. The results show that the IVPT data of rotigotine transdermal patch in three types of ex vivo mouse skin are well matched with the IVIVC of human PK data, among which the fitting result of rat is the best. It also shows that the in vivo skin absorption of HWY hairless rats is better than that of hydrophilic drugs in predicting the human skin absorption of lipophilic drugs; this method can be used to construct IVIVC of rotigotine transdermal patch between different species.
[0028] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for constructing a rotigotine transdermal patch IVIVC using isolated mouse skin, characterized in that: The following steps are involved: S1. Obtaining ex vivo animal skin: After killing the animal, cut the skin, wipe off the subcutaneous fat tissue with absorbent cotton, and retain the subcutaneous fascia tissue; S2. In vitro permeation experiment: Cut the rotigotine transdermal patch, remove the release film on the surface, stick the patch on the skin to be tested, and press to ensure that it is firmly adhered; fix the skin with a fixing clip and add PBS buffer solution with pH=6.5; Set the temperature and speed, use the PBS buffer solution with pH=6.5 as the receiving solution, take samples at 1, 2, 3, 4, 6, 8, 10, 12 and 24 h, and add an equal amount of isothermal blank receiving solution; S3. Calculation of IVIVC data: The IVPT data of ex vivo skin was processed to calculate the in vitro permeability Ft, the human body absorption rate Fa was calculated using the Wagner-Nelson equation, and a linear regression fit was performed on the in vitro permeability and human body absorption rates.
